GLUE ▲ +5.8% - Monte Rosa Therapeutics, Inc. $GLUE - Monte Rosa Therapeutics to Present Results of MRT-8102 GFORCE-1 Phase 1 Study in Subjects with Elevated Cardiovascular Disease Risk 30-SEP-2026 04:01 PM ET